Complexity, retinoid-responsive gene networks, and bladder carcinogenesis

Advances in Experimental Medicine and Biology

Volumn 462, Issue , 1999, Pages 449-467

  Hurst, R E ^a   Waliszewski, P ^a   Waliszewska, M ^a   Bonner, R B ^a   Benbrook, D M ^a   Dar, A ^a   Hemstreet III, G P ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID X RECEPTOR;

APOPTOSIS; BLADDER CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFERENCE PAPER; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PAPILLOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; TRANSITIONAL CELL CARCINOMA;

ATRA;

EID: 0033281458     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4737-2_35     Document Type: Conference Paper

References (92)

1. Lessons from hereditary colorectal cancer
2. Common patterns of genetic evolution in human solid tumors
3. Cancers beget mutations versus mutations beget cancers
4. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies
5. Cancer Statistics, 1995
6. Cancer Incidence in Five Continents. Age-specific and standardized incidence rates
7. Screening workers exposed to suspect bladder carcinogens
8. Superficial bladder cancer: Progression and recurrence
9. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis
10. Cancer as a disease of DNA organization and dynamic cell structure
11. Differentiation, cancer, and anticancer activity
12. Subversion of growth regulatory pathways in malignant transformation
13. Recessive genes in tumorigenesis
14. Participation of p53 protein in the cellular response to DNA damage
15. Proteoglycans as modulators of growth factors
16. Cytokines in context
17. Chemical and physical carcinogenesis: Advances and perspectives for the 1990s
18. Modulators of gap junction function: The scientific basis of epigenetic toxicology
19. Cellular epigenetics and the origin of cancer
20. Intermediate endpoint biomarkers for chemoprevention
21. Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis
22. Tumors of the urinary tract and prostate
23. Comparative flow and cytometric deoxyribonucleic acid studies on exophytic tumor and random mucosal biopsies in untreated carcinoma of the bladder
24. Mosaicism in human epithelium: Macroscopic monoclonal patches cover the urothelium
25. Two molecular pathways to transitional cell carcinoma of the bladder
26. Biomarkers in monitoring for efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide
27. Molecular genetic alterations in superficial and locally advanced human bladder cancer
28. Urine cytology in the detection of bladder cancer: A critical approach
29. Many growth factors may not be growth factors
30. Genetic errors, cell proliferation, and carcinogenesis
31. Modulation of growth factor responsiveness of murine mammary carcinoma cells by cell matrix interactions: Correlation of cell proliferation and spreading
32. Retinoids, retinoid-responsive genes, cell differentiation, and cancer
33. Chemoprevention
34. Retinoids and chemoprevention: Clinical and basic studies
35. Identification of 5,6-epoxyretinoic acid as an endogenous retinol metabolite
36. Biogenesis of retinoic acid from beta-carotene. Differences between the metabolism of beta-carotene and retinal
37. Modulation of cellular interactions by vitamin A and derivatives (retinoids)
38. Radioimmunochemical determination of cellular retinol- and cellular retinoic acid-binding proteins in cytosols of rat tissues
39. Retinoic acid-binding protein in normal tissues and experimental tumors
40. Molecular cloning of cDNA encoding a second cellular retinoic acid-binding protein
41. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein
42. The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 teratocarcinoma stem cells
43. Retinoic acid receptors and cellular retinoid binding proteins: Complex interplay in retinoid signaling
44. Role of retinoids in differentiation and carcinogenesis
45. Nuclear retinoid receptors and their mechanism of action
46. The retinoid signaling pathway: Molecular and genetic analyses
47. The nuclear receptor superfamily: The second decade
48. Identification of a receptor for the morphogen retinoic acid
49. A new retinoic acid receptor identified from a hepatocellular carcinoma
50. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor
51. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently
52. The RXR heterodimers and orphan receptors
53. Vertebrate receptors: Molecular biology, dimerization and response elements
54. Formation of retinoid X receptor homodimers leads to repression of T3 response: Hormonal cross talk by ligand-induced squelching
55. Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta I promoter by antagonizing AP-I activity
56. A new class of retinoids with selective inhibition of AP-I inhibits proliferation
57. 6′-substituted naphthalene-2-carboxylic acid analogs, a new class of retinoic acid receptor subtype-specific ligands
58. Activation of retinoid receptors RARα and RXRα induces differentiation and apoptosis, respectively, in HL-60 cells
59. Inhibition of carcinogenesis by retinoids
60. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation
61. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2
62. Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors
63. Inhibition of tumor promoter-induced transformation by retinoids that transrepress AP-1 without transactivating retinoic acid response element
64. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells
65. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma
66. Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse
67. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO
68. Chemoprevention of experimental bladder cancer
69. Prevention of recurrent superficial bladder tumors by oral etretinate: Preliminary results of a randomized, double blind multicenter trial in Switzerland
70. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors - Final analysis of a prospective, randomized multicenter trial in Switzerland
71. DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR
72. Megadose vitamins in bladder cancer: A double-blind clinical trial
73. Induction of thioguanine-resistant mutations in human uroepithelial cells by 4-aminobiphenyl and its N-hydroxyderivatives
74. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
75. Interaction of phenol red with estrogenic and antiestrogenic action on growth of human breast cancer cells ZR-75-I and T-47-D
76. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol- chloroform extraction
77. Quantitative changes in cytoskeletal and nuclear actin levels during cellular transformation
78. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action
79. Multiplicity generates diversity in the retinoic acid signalling pathways
80. Unique response pathways are established by allosteric interactions among nuclear hormone receptors
81. Hetero- and homodimeric receptors in thyroid hormone and vitamin A action
82. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice
83. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells
84. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials
85. Cytology of bladder cancer
86. Nuclear actin as a biomarker for bladder cancer risk assessment
87. Cellular F-actin levels as a marker for cellular transformation: Correlation with bladder cancer risk
88. Cellular f-actin levels as a marker for cellular transformation: Relationship to cell division and differentiation
89. DNA methylation errors and cancer
90. The cancer problem
91. The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers